Benefits on brain MRI lesion activity with daclizumab HYP compared with intramuscular interferon beta-1a are maintained through 144 weeks' treatment: Results from the DECIDE study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: b10253da5d2fb3a9c6b8b5e6c7c2904d0eefd1ab
First added on: Apr 30, 2026